Quality Assurance in Cervical Cytology
|
|
- Noah Reynard Porter
- 6 years ago
- Views:
Transcription
1 Quality Assurance in Cervical Cytology Shaira Sahebali 10 th June 2017 Overview l Definition l Application l Measurements l Achievement of required level of competence l External quality assessment 1
2 Definition l To attain and sustain a certain level of technical and diagnostic skills l Constant improvements in timing, performance and achievements of uniform quality l Systematic monitoring of results and parameters to detect, control and prevent mistakes l Histology AND cytology 2
3 How to evaluate? l Non-official g Internal consult: What do you think? g External consult g Statement in protocol = semi-official l Official g BELAC: Belgian Accreditation Institute 2006 g JCI: Joint Commission International 1994 g Other 3
4 Level of competence l Where do I want to go? g Minimal requirements ISO g Additional l Hospital l Clinicians l Department l How do I get there? l How do I stay there? Stages of quality control 4
5 Application on diagnostic chain l Pre-analysis g Clinical condition woman l Day of cycle l Post partum l Infections g Sample collection l Anatomy l Method & training of sample taker - Incomplete sampling - Loss of diagnostic cells Application on diagnostic chain l Pre-analysis g Clinical administration l Labeling sample l Order form g Lab administration l ID l Clinical information l Match with sample 5
6 Application on diagnostic chain l Analysis preparation technique g Laboratory procedures l Conventional LBC l Automation l Training lab personnel g Equipment l Preparation of slide l Computer-assisted processing/ screening g Staining and other tests l PAP, modifications l Immunocytochemistry l HPV Application on diagnostic chain l Analysis - diagnostics g Primary screening l Manual computer-assisted l Training CT, pathologist g Interpretation l Correlation between viewers (peer review) l Cytology versus biopsy g Reporting (post-analysis) l Bethesda, PAP, others l Management advice, explanatory notes 6
7 Quality Assessment Cycle items? item item Why does QA matter? l Avoid/ reduce faults g False negatives, false positives g Inadequate follow up g Unnecessary investigation and treatment l Uphold effectiveness of screening 7
8 Where can things go wrong? l Administrative g Correct identification g Data entry g Several links in the chain l Technical g # cells on slide g Staining; other reagents g Imaging Technical issues 8
9 Technical issues Where can things go wrong? l Diagnostics g Environment l Equipment l Space l Peace and quiet g Adequacy l # cells l Transformation zone l Feedback to clinician 9
10 Where can things go wrong? l Diagnostics g Search & Identify l Habituation, distraction l Identification of cells l Overconfidence, anxiety l Too many, too fast g Reporting l Training, experience l Confidence l Workload What to evaluate? l Technique l Diagnostics g Proficiency testing g Reporting l Accreditation l Laboratory organization l Performance 10
11 Measurement of results Test pos Disease No Disease Total RP (real positive) FP (false positive) Total # positive tests Pos.pred.value= RP/ (RP+FP) Test neg FN (false negative) RN (real negative) Total # negative tests Neg.pred.value= RN/ (RN+FN) Total Total # disease Total # no disease All= RP + FP + FN + RN Sens= RP/ (RP+ FN) Spec= RN/ (RN + FP) Pre-test Probability= (RP + FN)/ (All) Measurement of results l False positive (cytology > biopsy) g Lesion regressed g Lesion very small g Lesion not in biopsy g Cytological abnormalities overrated l False negative (cytology < biopsy) g Lesion not in cytology sample g Abnormal cells not on slide g Abnormal cells not recognized or interpreted wrong 11
12 Measurement of results l Threshold # false negatives g # ASC/ASC-US/ASC-H or LSIL g Comparison individual versus every-one g Document beforehand l Required level of competence l Measurements l Corrective actions l Positive predictive value l Referral value Measurement of results l Threshold # false negatives g # ASC/ASC-US/ASC-H or LSIL l ASC= 3-5%, of which ASC-H= 10% l ASC/SIL= 2-3:1 l hrhpv+ in ASC-US= 30%-50% g Ratio hides double faults g Ratio CT differs from CT + Path g Higher CT ratio yields better sensitivity 12
13 Achievement of required competence l During diagnostics g Review (10%) NILM, at risk cases g Pre- or review all slides l Rapid l CT or computer g Correlation CT supervisor (CT or pathologist) g 2nd reading 13
14 Achievement of required competence l After first diagnostics g HSIL review: History of 5 years l By various persons l Blind l Index case in test series g Correlation cytology histology l Collaboration with dept of gynecology for additional information g Correlation cytology HPV l Collaboration with dept of molecular biology Achievement of required competence l Periodical outside diagnostics g Internal IQA test g Compare within screening program l Correlation distribution diagnoses - Other labs - Epidemiology: Belgian Cancer Registry l Correlation HPV results l Patient history g Internal continuing education l Books, journals, slides 14
15 Achievement of required competence l Work meeting individual evaluation g Feedback diagnostics g Workload, reading speed, TAT l How to organize work g Levels of CT CT supervisor Head CT g Pathologists g Head of department l Ergonomics g Mens Sana in Corpore Sano Laboratory organization Head Pathologistsupervisors Head CT CT experts CT pool 15
16 Internal Quality Assessment l Technical check-ups g Personnel l Technical l Administration g Equipment l Diagnostics g Compose your own test series g Histologically proven if possible g All CTs and screening pathologists l Primary l Secondary 16
17 l If the number of samples decreases, maintenance of competence becomes more difficult l Triage sifts out the more difficult cases l How does vaccination influence this system? 17
18 External continuing education l Review sessions l Workshops, courses l Students, CTs and pathologists (intraining) l In group and individual The ideal external assessment 18
19 External Quality Assessment l Proficiency testing g National: WIV/ ISSP g Europe: AfaQap, SKML, UKAS g Other: CAP l Accreditation g BELAC g Other g ISO External Quality Assessment l How and what? g Technical g Diagnostics l Colleagues, guidelines l Evaluate slides, photos, scans l Depends in part on used technology/ guidelines l Educational or testing of expertise g Laboratory organization l Work practice l Ergonomics 19
20 CAP l Participants provide cases to archive l Conventional, SP, TP, mix l Manual screening l Response by fax or website l Mandatory test in USA g Only miss 1/10 g NO HSIL miss! Ypermangroup l Participants provide TP cases l Slides are imaged l Screen by reviewscope (or manual) l Response via website l Evaluation report l Yearly meeting g Diagnosis: absolute and corrected g Management: follow up advice g Technique/ use of scope 20
21 Reviewscope Yperman scoring algorithm ANTWOORD / DIAGNOSE NILM AGC/ASCUS LSIL HSIL ADCA/PCC NILM AGC/ASCUS LSIL HSIL ADCA/PCC
22 QUATE aptitude test l Quality Assurance, Training and Examination l International (EU) test for CTs who fulfill national accreditation criteria l Conventional and LBC l Written: 50 MCQ l Practical: screen 16 slides The ideal test l Cases of doubt; ASC-US? l NILM without proof? l How many cases in test series? l What is included in test series? l How many mistakes are allowed? g # g weight 22
23 Remember l Broader context g Clinician, molecular biologist g Hospital g Screening program l Important g HPV primary screening g Follow up References l g QA course l g European screening guidelines l Auger M. Cancer Cytopathol 2014 Jan l Cibas E.S. Am J Clin Pathol 129:
24 24
4. Monitoring of PAP test with Cervical Biopsy Correlations
Page 1 of 6 1. For cases of an HSIL Pap test with a discordant biopsy report where only the biopsy report is available, what action do you take? (check all that apply) Paper correlation without review
More informationCINtec PLUS and the Pap smear: a co-testing alternative
CINtec PLUS and the Pap smear: a co-testing alternative Rosemary Tambouret MD p16/ki67 (CINtec PLUS) and the Pap smear Rosemary Tambouret MD CINtec PLUS dual stain: p16 and Ki67 p16 is anti-proliferative
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationGOALS AND OBJECTIVES CYTOPATHOLOGY
GOALS AND OBJECTIVES CYTOPATHOLOGY LEVEL: PGY2, PGY4, PGY5 The 1st block in PGY2 is an introductory in nature and is followed by two more blocks in PGY-4 (please, see core rotation for PGY4 below) and
More informationNational Cervical Screening Program MBS Item Descriptors
National Cervical Screening Program MBS Item Descriptors Item Item descriptor 73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer
More informationDepartment of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018
Document Title: Department of Health Standard for the Cervical Cancer Screening Program Document Ref. Number: DOH/CCSC/SD/1.0 Version: 1.0 Approval Date: 08 May 2018 Effective Date: 13 May 2018 Last Reviewed:
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationAn Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program
An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program Susan Baum, MD, MPH NM Nurse Practitioner Council Annual Conference April 20, 2012 I have no commercial relationships related
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationHPV: cytology and molecular testing
HPV: cytology and molecular testing Human Papillomavirus and how we test for it at Medlab Central Palmerston North for Cervical Cancer prevention and management. Developed by Reem Mustafa Cytology and
More informationGoals and Objectives for Cytopathology Rotation
Goals and Objectives for Cytopathology Rotation Level: PGY3, PGY4, PGY5 The 1st block in PGY3 is an introductory in nature and is followed by three more blocks in PGY-4 (please, see core rotation for PGY4
More informationHow invasive cervical cancer audit affects clinical practice
How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive
More informationStreamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014
Streamlining Protocols-From Strategy to Implementation Doreen Ramogola-Masire Botswana UPenn Partnership 18-20 June 2014 Botswana-UPenn Partnership Partnership between Government of Botswana, University
More informationQuantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease
Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease Nahida Chakhtoura, MD, Leo Twiggs, MD, Timothy DeSantis, MD Claudia Werner, MD, William
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationDetails of HPV-based Cervical Cancer Screening in Turkey
Details of HPV-based Cervical Cancer Screening in Turkey Murat Gultekin, MD, Assoc. Prof., Gyn Oncol Divison Cervical Cancer in Turkey Incidence: 4-5 /100.000 (Years 2004-2015) Annual New Cases: 1.800
More informationGynecologic Cytology-Histology Correlation Guideline
Gynecologic Cytology- Correlation Guideline George G. Birdsong, MD and Joe W. Walker, Jr., MS, SCT(ASCP) CM Clinical Practice Committee Dr. Birdsong and Mr. Walker are grateful for extensive input from
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationEuropean Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationConflict of Interest. Thank you. I have no relevant conflicts of interest in regards to the content of this presentation.
What now... Conflict of Interest I have no relevant conflicts of interest in regards to the content of this presentation. Thank you Amy Clayton, MD Mayo Clinic Rochester, MN The Duke Experience 2005 2013
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationCytology Report Format
Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More informationAbnormal Spectroscopy Scans May Presage Persistent or Progressive Cervical Dysplasia
Abnormal Spectroscopy Scans May Presage Persistent or Progressive Cervical Dysplasia Leo B. Twiggs, M.D. Professor Emeritus University of Miami Miller School of Medicine Miami Florida USA Currently- Women
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationLaboratory Considerations
Laboratory Considerations In Support of HPV Vaccine Programs Elizabeth R. Unger PhD, MD Team Leader HPV Laboratory Centers for Disease Prevention and Control Towards Comprehensive Cervical Cancer Control:
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationCervical cancer screening in Norway
Cervical cancer screening in Norway «The future of cancer screening in Estonia: health benefits and best practices» 17 November 2016, Tartu Stefan Lönnberg Cancer Registry of Norway Screening governance
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationImplementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing
Implementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing Background In Nov 2015 following a review of evidence the UK National Screening Committee made a recommendation to the UK countries
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationGYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM
GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM The Department of Pathology and Laboratory Medicine University of Calgary, Faculty of Medicine Calgary Health Region and Calgary Laboratory Services Calgary,
More informationRisk : How does it define cervical cancer screening?
Risk : How does it define cervical cancer screening? Alan G. Waxman, MD, MPH Dept. of Obstetrics and Gynecology University of New Mexico The University of New Mexico Disclosures I have no commercial interests
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationSupplements to the European Guidelines on Prevention of Cervical Cancer
Asturias, 23 October, 2011 Asturias, 23 October Supplements to the European Guidelines on Prevention of Cervical Cancer M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat
More informationo 2-yearly (Pap test) o 18 to 69 years 1 o Registry reminder
Invasive cervical cancer cases per 100,000 Main changes from Dec 2017 The Renewed National Cervical Screening Program The Big Picture Brisbane 22 nd April 2017 Ian Hammond National Cervical Screening Program:
More informationCase Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationThe Bethesda System: Updates for th Cytopathology Congress Bursa, Turkey October 14, 2015
HARVARD MEDICAL SCHOOL The Bethesda System: Updates for 2015 6th Cytopathology Congress Bursa, Turkey October 14, 2015 David C. Wilbur, M.D. Dept. of Pathology Massachusetts General Hospital DISCLOSURES
More informationThe new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationGuidelines, Policies and Statements
FS 557931 Guidelines, Policies and Statements C2 Statement on the Practice of Ultrasound by Sonographers Formerly Role of the Sonographer February 1996, Revised September 1999, November 2006, July 2007,
More informationJanuary 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs CMS FACT SHEET FOR IMMEDIATE RELEASE Contact:
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCervical Cancer Screening Guidelines Update
Frontier AIDS Education and Training Center Cervical Cancer Screening Guidelines Update Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics Frontier AETC, Medical Program Director
More informationThe Future of Cervical Screening. Jenny Ross
The Future of Cervical Screening Jenny Ross Introduction Cervical cancer and the Pap smear History of cervical screening in Australia New knowledge about HPV and cervical cancer HPV Vaccination Program
More informationPreventing cervical cancer Australia. The Renewed National Cervical Screening Program 2019 Common Questions and Cases
The Renewed National Cervical Screening Program 2019 Common Questions and Cases Preventing cervical cancer Australia - National HPV vaccination program - The National cervical screening program Annabelle
More informationMake the BD FocalPoint GS Imaging System your guide in cervical cytology screening. Computer-guided screening
Computer-guided screening Liquid-based cytology Immuno-chemistry Make the BD FocalPoint GS Imaging System your guide in cervical cytology screening Directs your attention to slides most likely to contain
More informationCytopathology Education and Technology Consortium
American Society of Cytopathology Executive Board Meeting AGENDA May 3, 2010, 7:30 AM 4:00 PM, Central Valencia Room Intercontinental Hotel Chicago, Illinois Cytopathology Education and Technology Consortium
More informationHuman Papillomavirus Genotyping and Cervical Smear in Duhok/Iraq
Human Papillomavirus Genotyping and Cervical Smear in Duhok/Iraq Intisar Salim Pity (Professor pathology) MBChB, MSc, FIBMS Hanaa Mohammad Abdo (MSc microbiology) Amer A. Goreal (Microbiology) MBChB, FIBMS
More informationApplying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice
Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice Dr. Gregory Flynn CEO, Institute for Quality Management in Healthcare Managing Director, Quality Management
More information6 th EFC Satellite meeting, Saturday 1 st December 2018
6 th EFC Satellite meeting, Saturday 1 st December 2018 Introduction Pekka Nieminen President-elect of the European Federation for Colposcopy, Department of Obstetrics and Gynaecology, Helsinki University
More informationNATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor
More informationHPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital
HPV Primary Screening Update Prof. Vu Ba Quyet Director of NO&G hospital 1 Who can we not worry about? 2 Key questions Who should be screened? Starting age? Ending age? How often? How to manage results?
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationValidity of Colposcopy in the Diagnosis of Early Cervical Neoplasia. Dr. Olaniyan Olayinka Babafemi
Validity of Colposcopy in the Diagnosis of Early Cervical Neoplasia Dr. Olaniyan Olayinka Babafemi Objective QUANTIFICATION OF PERFORMANCE OF COLPOSCOPY IN DIAGNOSIS OF EARLY CERVICAL DISEASE TO ASSESS
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationVALGENT (validation of HPV genotyping assays) implications for the introduction of primary HPV screening
VALGENT (validation of HPV genotyping assays) implications for the introduction of primary HPV screening M Arbyn 1 (1) Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium;
More informationQA and Quality Indicators for Cervical Cancer Screening Programs. Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy
QA and Quality Indicators for Cervical Cancer Screening Programs Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy Disclosures No financial relationships or conflict of interest to disclose
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More informationBeyond Pap Morphological Triage: p16/ki67 Dual Staining
Moving away from Beyond Pap Morphological Triage: p16/ki67 Dual Staining Nicolas Wentzensen MD, PhD, MS Deputy Chief, Clinical Genetics Branch; Head, Clinical Epidemiology Unit National Cancer Institute
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationProposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns
Proposed new national cervical screening program Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns www.drelizabethjackson.com Cervical cancer in Australia 12th most common cancer affecting Australian
More informationHPV Primary Screening in the United States
IFCPC 15th World Congress May 2014, London, UK. HPV Primary Screening in the United States E.J. Mayeaux, Jr., M.D. Professor and Chairman Department of Family and Preventive Medicine Professor of Obstetrics
More informationThe Role of The Advanced Practitioner in Cytology
The Role of The Advanced Practitioner in Cytology Margaret Morgan Head of Service Cellular Pathology GSTS Pathology London Odense, Denmark 5 th March 2011 St Thomas Hospital London County Down Overview
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationSE Coast Cervical Screening QARC Interim Guidance for laboratories on cervical sample acceptance
SE Coast Cervical ing QARC Interim Guidance for laboratories on cervical sample acceptance List of accepted reasons/categories for sample rejection and inadequate cytology reports in SE Coast Version 6,
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationScreening for the Precursors of Cervical Cancer in the Era of HPV Vaccination. Dr Stella Heley Senior Liaison Physician Victorian Cytology Service
Screening for the Precursors of Cervical Cancer in the Era of HPV Vaccination Dr Stella Heley Senior Liaison Physician Victorian Cytology Service Victorian Cytology Service Dr Stella Heley Dr Siobhan Bourke
More informationScottish Pathology Network (SPAN) Progress Report Oct 2008
Scottish Pathology Network (SPAN) Progress Report Oct 2008 SPAN SPAN Pathology configuration in Scotland Operation of the network Context (diagnostics in Scotland) Common challenges Concerted responses
More informationThe cross sectional study design. Population and pre-test. Probability (participants). Index test. Target condition. Reference Standard
The cross sectional study design. and pretest. Probability (participants). Index test. Target condition. Reference Standard Mirella Fraquelli U.O. Gastroenterologia 2 Fondazione IRCCS Cà Granda Ospedale
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationImplementation of a Research-Robust Colposcopy Management Program within the Electronic Medical Record System
Implementation of a Research-Robust Colposcopy Management Program within the Electronic Medical Record System Lonky NM*, Cannizzaro N, Xu L, Castaneda A, Stowe T, Hawk S, Chao C Southern California Permanente
More informationIt s a Gas! Issues in the Blood Gas Laboratory. D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC
It s a Gas! Issues in the Blood Gas Laboratory D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC Learning Objectives After participating in this session, you will be able
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationMaster. Cytopathology Checklist. Every patient deserves the GOLD STANDARD... CAP Accreditation Program
Master Every patient deserves the GOLD STANDARD... Cytopathology Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 07.28.2015
More informationUpdated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.
Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D. 27 May, 2014 London, England Faculty Disclosure X No, nothing to disclose Yes, please specify
More informationMultimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy
Multimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy L Twiggs, T De Santis, NM Chaktoura, D Ferris, L Flowers, M Lashgari, E Wilkinson, S Bambot, A Agrawal, and D Mongin EUROGIN
More informationHosp Lab Management (HLM) Service. HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow
Hosp Lab Management (HLM) Service HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow Women s Healthcare: Demography End of uncertainties Actual Disease Burden: Delhi NCR: FY2012-13
More informationCervical Cancer Research in South Africa
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervical Cancer Research in South Africa Lynette Denny Department Obstetrics and Gynaecology, University of Cape Town/ Groote Schuur Hospital
More informationCan LBC Completely Replace Conventional Pap Smear in Developing Countries
The Journal of Obstetrics and Gynecology of India (January February 2019) 69(1):69 76 https://doi.org/10.1007/s13224-018-1-7 ORIGINAL ARTICLE Can LBC Completely Replace Conventional Pap Smear in Developing
More informationCorrespondence should be addressed to Xavier Catteau;
ISRN Obstetrics and Gynecology, Article ID 536495, 5 pages http://dx.doi.org/10.1155/2014/536495 Research Article Evaluation of the Oncogenic Human Papillomavirus DNA Test with Liquid-Based Cytology in
More informationIl ruolo delle VEQ per la sicurezza trasfusionale
Il ruolo delle VEQ per la sicurezza trasfusionale The role of EQA for transfusion safety Giulio Pisani CNCF Ist. Sup. Sanità Global Blood Product Safety, Roma 10 aprile 2019 Blood transfusion is an essential
More informationClinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years
Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages 21-39 years Michelle I. Silver, PhD, ScM Cancer Prevention Fellow National Cancer Institute Division of Cancer
More informationPortinari: A Data Exploration Tool to Personalize Cervical Cancer Screening
Portinari: A Data Exploration Tool to Personalize Cervical Cancer Screening Sagar Sen, Manoel Horta Ribeiro, Raquel C. de Melo Minardi, Wagner Meira Jr., Mari Nygård Certus V&V Center and HPV Research
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationLCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
More informationAgreement Between Cytotechnologists and Cytopathologists as a New Measure of Cytopathologist Performance in Gynecologic Cytology
Agreement Between Cytotechnologists and Cytopathologists as a New Measure of Cytopathologist Performance in Gynecologic Cytology Andrew M. Quinn, MD 1 ; Abu T. Minhajuddin, PhD 2 ; Linda S. Hynan, PhD
More information